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The Pneumonia Etiology Research for Child Health (PERCH) project is a 7-country, standardized,
comprehensive evaluation of the etiologic agents causing severe pneumonia in children from developing
countries. During previous etiology studies, between one-quarter and one-third of patients failed to yield an
obvious etiology; PERCH will employ and evaluate previously unavailable innovative, more sensitive
diagnostic techniques. Innovative and rigorous epidemiologic and analytic methods will be used to establish
the causal association between presence of potential pathogens and pneumonia. By strategic selection of
study sites that are broadly representative of regions with the greatest burden of childhood pneumonia,
PERCH aims to provide data that reﬂect the epidemiologic situation in developing countries in 2015, using
pneumococcal and Haemophilus inﬂuenzae type b vaccines. PERCH will also address differences in host,
environmental, and/or geographic factors that might determine pneumonia etiology and, by preserving
specimens, will generate a resource for future research and pathogen discovery.
The Pneumonia Etiology Research for Child Health
(PERCH) project is a multi-country, standardized, and
comprehensive evaluation of the etiologic agents caus-
ing severe and very severe pneumonia among children
in developing countries. PERCH will be the largest and
most comprehensive study of childhood pneumonia
etiology thus far conducted. By rigorously updating
and expanding our understanding of pneumonia
pathogens, we expect that PERCH will directly lead
to improved prevention strategies and therapies for
one of the leading causes of child death and a major
cause of serious illness and hospitalizations in children
around the globe.
Our current understanding of pneumonia etiology was
largely developed from research studies in the 1970s
through the early 1990s. These ﬁndings showed that
the majority of fatal pneumonia cases in children is
due to 2 bacteria—Streptococcus pneumoniae and
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occurred primarily in communities with high levels of child
mortality, typically impoverished settings that lack access to
basic healthcare such as antibiotics and oxygen therapy
[1, 2].
Substantial changes in disease burden, prevalence of co-
morbid conditions, or other factors that may affect the eti-
ology of pneumonia have occurred since the last systematic set
of etiology studies in children were undertaken. For example,
most of the evidence on which current empiric treatment
algorithms for pneumonia in developing countries are based
was collected before the human immunodeﬁciency virus
(HIV) pandemic and in the absence of antiretroviral treat-
ment of HIV-infected children, before recent substantial
successes in malaria control, and before the widespread
deployment of Hib and pneumococcal conjugate vaccines.
Furthermore, lower rates of very severe malnutrition and
increased urbanization and crowding may also impact
the etiology of pneumonia and make pneumonia etiology
data obtained in the 1980s less relevant to policy today.
Simply put, continued use of clinical algorithms based on
the assumption that predominant causes of severe
pneumonia are almost always H. inﬂuenzae and S. pneu-
moniae may lead to treatments that are not appropriate for
a child’s actual infection and will miss the opportunity to guide
vaccine development against important new or unrecognized
pathogens.
STUDY DESIGN, TESTING, AND ANALYSIS
Although inferences regarding pneumonia etiology can be
drawn from many different study designs, including cohort
studies, case series, and treatment or intervention trials, the
PERCH study has been designed as a case-control study that
aims to enroll 6000 patients hospitalized for severe or very
severe pneumonia and 6000 controls selected randomly
from the community. The main reasons for this design are
as follows: (1) the use of hospitalized patients, as opposed to
those observed outside of facilities, is necessary to assure that
we can safely collect a range of specimens from patients and
that we gain the efﬁciency of testing only those with severe
and very severe pneumonia; and (2) the inclusion of controls
is important to guide the interpretation of results from the use
of highly sensitive detection tests on upper respiratory tract
specimens and to facilitate the identiﬁcation of risk factors
for pneumonia and/or speciﬁc etiologies. Although PERCH
recognizes that pneumonia is an important illness in neonates
and that important questions remain regarding the etiologies
of serious pneumonia in this age group, it was considered
sufﬁciently important and unique to require its own study, and
thus PERCH focuses on children aged 1–59 months old.
PERCH will employ and evaluate innovative diagnostic tech-
niques and analytic methods that were not available during
previous etiology studies. The understanding that H. inﬂuenzae
and S. pneumoniae are the main causes of fatal pneumonia in
children is supported primarily by 2 types of evidence: ﬁrst,
laboratory diagnoses from a limited number of lung aspi-
ration studies of severe pneumonia cases seen at hospital
facilities, and second, trials of antibiotic therapy and Hib
and pneumococcal vaccines. In the latter instance, the pro-
portionate reduction in cases of pneumonia or fatal pneu-
monia is used as a proxy for the proportion of cases or deaths
due to the targeted bacterium, or speciﬁcally, Hib and/or
pneumococcus. In recent clinical trials, Hib and pneumo-
coccal conjugate vaccines have prevented about one-ﬁfth
to one-third of x-ray conﬁrmed pneumonia with alveolar
consolidation [3–10].
Although current evidence suggests that fewer fatal pneu-
monia cases are due solely to viral infections, laboratory
investigations of children in developing countries and else-
where often show that respiratory syncytial virus, inﬂuenza
virus, and parainﬂuenza virus are identiﬁed from a large
proportion of hospitalized patients with lower respiratory
tract illness [11]. In addition, there is increasing recognition
of the importance of mixed infections and the interactions
between viral and bacterial infections, for example, inﬂuenza
virus infections that predispose to bacterial pneumonia [12].
Nevertheless, even in comprehensive studies of pneumonia
etiology, between one-quarter and one-third of patients fail
to yield an obvious etiology, suggesting that better, more
sensitive laboratory methods are needed [1]. However, more
sensitive tests may identify the presence of commensal patho-
gens that may not be the etiologic cause of the pneumonia
episode being studied. Innovative or more rigorous epidemi-
ologic methods are needed to establish the causal association
between isolation of a potential pathogen and the pneumonia
case being studied [11, 13].
Although a recent survey of the literature and the ﬁeld
indicates that .50 studies of pneumonia etiology in addition
to PERCH are underway, the PERCH project aims to make
a number of unique contributions [14]. The PERCH project
includes 7 sites from diverse geographic areas and disease
ecologies that are expected to represent the epidemiologic
settings where most severe and fatal pneumonia will occur
in the coming decades. It will also use standardized and
innovative laboratory, clinical, specimen collection, and
statistical techniques and comprehensive laboratory testing
of body ﬂuid and tissue specimens. By selecting sites that are
geographically and epidemiologically diverse, PERCH aims to
address differences in host, environmental, and/or geo-
graphic factors that might determine pneumonia etiology.
By assuring rigorous adherence to standard laboratory,
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the likelihood that any observed differences in etiology are
artifacts that follow from differences in methods across
sites. By employing the most recent laboratory and digital
diagnostic methods (eg, digital auscultation recordings and
digital radiographs of the chest) and preserving specimens
for future research and pathogen discovery, the PERCH
project will also generate a resource for pneumonia etiology
research that will last beyond its immediate timelines.
Most pediatric pneumonia etiology studies attempt to as-
cribe a causative organism by collecting a limited number of
diagnostic specimens, such as a blood and upper respiratory
tract cultures. A few studies include a lower respiratory tract
specimen obtained from bronchoalveolar lavage, lung aspi-
rate, or occasionally, an induced sputum sample, and rarely,
postmortem tissue specimens, and some more recent studies
have included nucleic acid testing on specimens. PERCH will
collect a comprehensive array of specimens, including naso-
pharyngeal, oropharyngeal, and induced sputum specimens
from the respiratory tract, blood specimens, and urine
specimens from all patients, and in some study sites, lung
aspirates from patients with pneumonia and/or lung biopsies
from deceased patients. Each of these specimens will be tested
using a broad panel of diagnostic techniques that seek a large
number of potential pathogens.
By collecting multiple specimens from the same patient and
from community controls without pneumonia, PERCH will
provide a comprehensive selection of pathogen data that can
be used to validate (or refute) the results from other studies in
which only 1 or 2 specimens are collected or in which only
case patients are studied. For example, by comparing the
ﬁndings from lung aspirates or pleural ﬂuid, induced spu-
tum, and the nasopharynx in the same patient, PERCH will
be able to determine whether the concordance of results
might allow future studies of pneumonia etiology to utilize
induced sputum specimens as a complement to other more
invasive, less frequently obtained specimens. Similarly, by
comparing ﬁndings from multiplex polymerase chain re-
action (PCR) in both patients with pneumonia and repre-
sentative controls from the community without pneumonia,
PERCH provides useful information on the strength of the as-
sociation between a positive test result and pneumonia that
would be absent in studies of only case patients.
PERCH is aiming both to study the association of positive
tests with severe and very severe pneumonia and to determine
the attributable fraction of pneumonia cases associated with
an etiology or mixed infections. With multiple specimens
and multiple tests on those specimens, the volume of data
collected by PERCH therefore presents analytic challenges
in interpreting detection of multiple pathogens and dis-
tinguishing infection from causation. For example, in cases
am u l t i p l e xP C Rt e s tt h a tc a nd e t e c t.30 unique pathogens
will be applied on both nasopharyngeal and induced sputum
specimens. Thus, PERCH is generating both large volumes
of data and potentially correlated results that do not meet
the standard assumption of ignorable correlation among
regressors that generally underlie standard statistical meth-
ods used in the analysis of case-control studies (eg, logistic
regression).
Thus, in PERCH we are aiming to develop an innovative sta-
tistical approach to model the attributable risk of pneumonia for
each of these pathogens that can handle the complexity of the
PERCH data set and address the correlation among pathogen
infections in the presence of possible measurement errors. The
proposed approach treats the multiple infectious agents as an
unobserved or latent vector of variables, the values of which are
informed by the pathogen measurements, pneumonia status,
and covariate values. Speciﬁcally, the approach to statistical
analysis being developed by PERCH aims to estimate (1) the
prevalence of infection for each pathogen (or combination of
pathogens) of interest among patients hospitalized with se-
vere pneumonia and (2) the attributable risk for each
pathogen as a putative cause of severe pneumonia in hospitalized
patients. It can also estimate the proportion of cases with
no pathogen identiﬁed, a group that will be a high priority for
pathogen discovery efforts.
The research approaches used in PERCH were built on
the experience of past pneumonia etiology studies such as
the Board of Science and Technology in International De-
velopment (BOSTID) sponsored etiology projects of the
1980s, [15] the cumulative experience of study teams at
Johns Hopkins Bloomberg School of Public Health (JHSPH)
and the PERCH sites, and with expert input from the Pneu-
monia Methods Working Group (PMWG). The PMWG
comprised 16 international experts from 10 different coun-
tries with backgrounds in clinical medicine, laboratory sci-
ences, and epidemiology. The working group was charged
with helping to resolve key methodologic issues in the design
and conduct of pneumonia etiology research studies. The
PERCH team provided the PMWG with 27 background
documents and reviews on 20 topics and solicited feedback
or recommendations on 90 strategic questions. The PMWG
met twice in person and several times by teleconference
during which they provided recommendations and, where
needed, suggested additional data that needed to be collected
in order to resolve any key uncertainties. The background
documents to the PMWG and their recommendations are
available on the PERCH Web site (http://www.jhsph.edu/
ivac/perch.html).
In many ways, the BOSTID studies represent the last
major, multisite effort to study pneumonia etiology around
the world. This project included 12 sites around the world
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mation on both upper and lower respiratory tract infections
[15]. However, despite annual meetings of investigators, there
remained substantial heterogeneity across the sites in the
laboratory and clinical methods used that complicates efforts
to draw inferences by comparison across sites [16].
THE PERCH SITES
Representative sites and standardized study and analytic
methods help us with extrapolating the results from PERCH
sites to other areas. In PERCH, the study aims to include data
from sites that are representative of the epidemiologic set-
tings that we project will prevail in 2015 and onward. Spe-
ciﬁcally, PERCH assumes that from 2015 onward, with
support from the Global Alliance for Vaccines and Immu-
nization (GAVI) alliance, Hib and pneumococcal vaccines
will likely be used in the routine childhood immunization
programs of more than three-fourths of the world’s poorest
countries. In addition, although malaria and HIV infection
will continue to be important in pediatric populations in
some geographic foci, the prevalence of these two co-infections
will be low to moderate in most parts of the world as
a consequence of both increasing access to malaria control
interventions and expanded HIV prevention and treatment
programs. Because these changes will affect pneumonia eti-
ology, PERCH has selected sites with the intention that these
sites will produce data by 2014 that will be representative for
most areas from 2015 onward. All of the PERCH sites have
begun ofﬁcial enrollment between August and December 2011.
By 31 December 2013, therefore, PERCH aims to have com-
pleted 2 full years of enrollment in each of the 7 sites.
The 7 PERCH sites were selected by an open, competitive
process with proposals reviewed by international experts
and scored according to objective criteria. These sites repre-
sent areas where Hib and/or pneumococcal conjugate vac-
cines are routinely used (except Thailand), but they also
represent a set of diverse epidemiologic settings that include
t h e2g e o g r a p h i cr e g i o n s( A s i aa n dA f r i c a )( Figure 1)w h e r e
the vast majority of the world’s severe and fatal pneumonia
cases occur, a range of economic backgrounds (low-income,
lower middle-income, and upper middle-income countries),
urban and rural environments, variations in HIV infection
and malaria prevalence, differences in altitude, and varia-
tions in the use of cooking and heating fuels (Table 1)E a c h
of these factors potentially contributes to variations in the
etiologic spectrum or burden of pneumonia in children.
Bangladesh Site
This Bangaldesh PERCH study represents a joint collabora-
tion between the International Centre for Diarrhoeal Disease
Research, Bangladesh (ICDDR,B) as an international research
facility and the Government of Bangladesh, represented by
the Institute of Epidemiology, Disease Control and Research.
Two sites are involved, one urban and the other a rural
center, each backed by well-deﬁned catchment areas with
ongoing population-based demographic and morbidity
surveillance.
The sites where the PERCH study will recruit patients
and controls includes 2 facilities: the Dhaka and Matlab
hospitals of ICDDR,B (in the Dhaka and Chittagong divisions
of Bangladesh, respectively); the former serves an urban
population and the latter a rural population. The Dhaka
hospital is a 350-bed facility supported by the Kamalapur
Figure 1. Map of study sites of the Pneumonia Etiology Research for Child Health project.
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morbidity surveillance among a population of 350 000, of
whom 11.5% are children ,5y e a r so l d[ 17, 18]. Kamalapur
has been involved in pneumonia studies since 1998 and has
conducted pneumonia etiology surveillance since 2004 [19].
The Matlab hospital is a 140-bed facility and is supported
by long-standing demographic and morbidity surveillance
among a population of 114 000. Both hospitals have dedi-
cated pneumonia wards. These sites represent both urban
and rural communities typic a lo fm u c ho fs o u t hA s i a .
The Gambia Site
In the Gambia, the PERCH study will be conducted in the
B a s s eﬁ e l ds i t eo ft h eU KM e d i cal Research Council (MRC)
Gambia, which has a long history of local and multicenter
research of infectious diseases. The childhood pneumonia
research program is well established, notably including large-
scale conjugate Hib and pneumococcal vaccine ﬁeld trials and
a range of other clinical pneumonia studies. The Gambia was
the ﬁrst country in Africa to introduce conjugate Hib vaccine
into its routine immunization schedule in 1998 and in-
troduced conjugate pneumococcal vaccine in 2009. Ongoing
efforts are underway to conduct comprehensive pneumo-
coccal surveillance and assess the impact of the vaccine on
pneumococcal disease and pneumonia rates. The MRC’s
Basse site, which is a rural site in the eastern end of the
country, has a well-established demographic surveillance
system and a partnership with the Gambia government
health services. This site will serve as the site for the
PERCH project, thereby providing representation of a rural,
low-HIV-seroprevalence, African setting with seasonal malaria
transmission.
Kenya Site
Kenya was one of the ﬁrst African countries to incorporate
Hib and pneumococcal conjugate vaccines into its routine
immunization program [20]. The PERCH site is the Kenya
Medical Research Institute-Wellcome Trust Research Programme
in Kiliﬁ, on the Indian Ocean coast. This research program
began in 1989 as a collaboration between the Kenya Medical
Research Institute, the Wellcome Trust of Great Britain, and
Oxford University. The program’sl a b o r a t o r i e sa r el o c a t e di m -
mediately adjacent to Kiliﬁ District Hospital, and the clinical
scientists at the program run the hospital’s pediatric service.
A population of 250 000 people living around the hospital
are followed in a demographic surveillance system (DSS) with
4-monthly household visits. The Kiliﬁ site is currently mon-
itoring the comprehensive impact of pneumococcal conjugate
vaccine use on pneumococcal disease and pneumonia rates in
persons of all ages.
The site is well positioned to conduct PERCH because
the activities of the clinical service, the laboratories, and the
DSS are linked at each point of contact by real-time data entry
into a comprehensive relational database. Kiliﬁ District
Hospital, which is the only inpatient facility in Kiliﬁ district,
admits 4500 children per year, of whom 60% come from
within the DSS area [21]. Ten years ago malaria was the
dominant cause of morbidity, but now, with effective malaria
treatment and prevention in place, pneumonia and neonatal
illnesses are the commonest causes of admission [22]. The
Table 1. Pneumonia Etiology Research for Child Health Site Country Descriptions
Country
2009
Population,
Thousands
a
2009
GNI Per
Capita, US$
a
2009 U5
Mortality
Rate
a
2009
Infant
Mortality
Rate
a
2009 HIV
Infection
Prevalence
Among Women
15–24 Years Old
a
Malaria
Incidence
Rate
b
Hib Vaccine
Introduction
Date
c
PCV
Introduction
Date
Bangladesh 162 221 590 52 41 ,0.1 . July 2009 January 2013
d
Gambia 1705 440 103 78 2.4 . January 1997 August 2009
Kenya 39 802 770 84 55 4.1 0.19 January 2001 February 2011
Mali 13 010 680 191 101 0.5 0.37 January 2008 March 2011
South Africa 50 110 5770 62 43 13.6 0.00 January 1999 November 2009
Thailand 67 764 3760 14 12 .. Not routine Not routine
Zambia 12 935 970 141 86 8.9 0.33 February 2004 July 2012
d
Abbreviations: GNI, gross national income; Hib, Haemophilus inﬂuenzae type b; HIV, human immunodeﬁciency virus; PCV, pneumococcal conjugate vaccine; U5,
under 5.
a Source: United Nations Children’s Fund, State of the World’s Children 2011 (http://www.unicef.org/sowc2011).
b Source: Roll Back Malaria Partnership (http://www.rollbackmalaria.org/partnership/wg/wg_monitoring/docs/annexes_ARFek4.pdf; accessed 30 November
2011).
c Source: Vaccine Information Management System (http://www.jhsph.edu/ivac/vims.html; accessed 30 November 2011).
d Forecasted.
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in East Africa.
Mali Site
In Mali, the proposed site for conducting the PERCH case-
control study is Hospital Gabriel Toure ´ (HGT), where nearly
all pediatric hospital admissions in Bamako take place. Each
year, HGT treats 25 000 children as outpatients and admits
5000 others (most ,5 years old). Most children admitted to
HGT are very ill. A survey in 2000 revealed that 71% of all
admissions to HGT among children ,16 years old were for
infectious diseases and 21% of all admitted children died [23].
The study will be conducted by investigators at Centre pour
le De ´veloppement des Vaccins, Mali, a center established as
a collaboration between the Ministry of Health of Mali and
the University of Maryland School of Medicine in the United
States, which is responsible for research and training in
tropical diseases. With a high infant mortality rate, and
a substantial burden of malaria but low to moderate HIV sero-
prevalence, this site represents large portions of West Africa.
South Africa Site
The PERCH study site is in Soweto, an urban low-income
community with a diversity of ethnic backgrounds. Although
the majority of households have access to running water,
25% of families live in informal settlements and use fossil
fuels for heating and cooking. The community is severely
affected by HIV, with one-third of mothers and at least 5%
of children being HIV infected. The mortality rate of chil-
dren ,5 years old in South Africa, including the study site,
increased from 60 to 69 deaths per 1000 live births from
1990 through 2005 [24]. Fifty-seven percent of all deaths
occur in HIV-infected children, of which at least one-third
are due to pneumonia even in the era of antiretroviral
therapy [25].
There are 23 primary health care (PHC) clinics in the
Soweto region and a single public hospital, the Chris Hani
Baragwanath Hospital (CHBH), which is the sole referral
hospital for all these PHC clinics. All immunization in the
community occurs at 1 of the 23 PHC clinics and vaccines are
provided free of charge, with minimal numbers of children
being immunized through the private sector, where fees are
charged. None of the PHC clinics admit children with severe
pneumonia. All severe pneumonia cases are referred to
CHBH, the largest hospital in the Southern Hemisphere,
with 450 pediatric beds with an average occupancy rate of
80%. The hospital provides free secondary and tertiary
care to the population of Soweto. An estimated 90% of
all hospitalizations from the community occur at CHBH.
All health care for children ,6 years old, including diag-
nostic tests and treatment, provided at the hospital and
PHC clinics are free of charge. There is, however, a very low
threshold for referring children to the hospital for evaluation
and further management of pneumonia. Travel to the hos-
pital is supported either through readily available public
transport or by ambulance if clinically indicated. Hib vaccine
was introduced in 1999 and pneumococcal conjugate vaccine in
2009. There is an active, ongoing pneumococcal conjugate
vaccine impact evaluation that will evaluate vaccine effec-
tiveness for prevention of pneumonia and invasive pneu-
mococcal disease. This site represents an urban, malaria-free
setting with high HIV infection prevalence.
Thailand Site
In Thailand, the PERCH study will be implemented by
the International Emerging Infections Program, part of
a formal collaboration between the Thailand Ministry of
Public Health and the US Centers for Disease Control and
Prevention. The study will be conducted in 2 rural provinces,
Table 2. Pneumonia Etiology Research for Child Health Governance Structures and Responsibilities
PERCH Body Responsibilities
Executive committee Charged with overall governance of the study, including publication of ﬁndings, sharing of study
results, reviewing and approving substudies, management of biorepository, resolving
implementation issues, monitoring of site performance, and establishing and maintaining
standards
Expert group Primary responsibility is to provide sound, strategic advice during the conduct of the study;
represents a ‘‘pre–peer review’’; provides links with the external research community and
provides a backward link with the Pneumonia Methods Working Group, which guided the
preliminary phase of PERCH
Working groups (laboratory,
clinical/epidemiology,
data, and analysis)
Charged with operations and coordination; responsible for establishing, maintaining, and
monitoring standardization across sites; will collaborate as needed, with questions from sites
directed to the working group leaders; chair is responsible for organizing teleconferences and
assuring that each meeting is productive and effective
Operational team Responsible for regular monitoring of study progress at each site, clariﬁcation of operational
issues that have been decided elsewhere, identiﬁcation of issues that require attention of the
working group, and assuring implementation of decisions of the working group at sites
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border and Nakhon Phanom province, which borders Laos
in northeastern Thailand. Active, population-based pneu-
monia surveillance is ongoing in all 20 hospitals in both
provinces. Pneumonia epidemiology in the 2 provinces is
similar except for the higher incidence of melioidosis in
Nakhon Phanom, which is typical of northeastern Thailand.
The PERCH study will be conducted in the 2 largest hospitals
in each province. Unlike at the other PERCH sites, Hib and
pneumococcal conjugate vaccines are available on the private
market but are not routinely used for all children in the
national immunization program. This site represents a rural/
periurban region typical of much of Southeast Asia inclu-
ding Thailand and its immediate neighbors, many of whom
are not currently using Hib and pneumococcal conjugate
vaccines for routine immunization of all children.
Zambia Site
The Zambia PERCH study site will be located at University
Teaching Hospital (UTH), a 1500-bed academic center and
tertiary care facility with 425 pediatric inpatient beds located
in the capital city, Lusaka, and the home of Zambia’s only
medical school. In 2008 there were a total of 14 923 inpatient
pediatric admissions, 3467 (23%) of which were for acute
respiratory illness and 1035 (30%) of which occurred in
children ,5 years old. The case fatality rate of severe pneu-
monia was 25.8%. UTH serves the greater Lusaka district, an
area of 70 square kilometers and a population of 1.3 million.
Hib vaccine is routinely used and, with support from the
GAVI alliance, pneumococcal conjugate vaccine is expected
to be routinely used in Zambia by 2013. With relatively high
rates of HIV infection, ongoing malaria in some areas, and
a poor urban environment, Lusaka is representative of many
parts of Africa.
THE CONDUCT OF PERCH
With .30 case report forms, an anticipated enrollment of
.12 000 patients and controls, and a large number of patient
specimens to track, PERCH has contracted with the EMMES
corporation (Rockville, MD) to develop an electronic data
system to capture all the data from each site and to manage
Figure 2. Organizational diagram of the governance structures of the Pneumonia Etiology Research for Child Health project. Abbreviations: DCC, Data
Coordinating Center; epi, epidemiologic; lab, laboratory; PI, principal investigator.
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regular reports to track the accrual of patients and quality
indicators of study performance are generated by EMMES
a n ds h a r e dw i t ht h eP E R C Hc o r et e a ma tJ H S P Ha n dw i t h
the site investigators. The PERCH team, including the site
investigators and the core team at JHSPH, are developing an
overall analysis plan for PERCH. Epidemiologists and bio-
statisticians at JHSPH are available as a resource to perform
these analyses.
To assure that the PERCH study is conducted in compli-
ance with recognized ethical standards for research, the
PERCH protocol has been reviewed by 10 institutional re-
view boards (IRBs). The IRB at JHSPH reviewed the overall
clinical protocol. The protocol was then adapted at each local
site and reviewed by the local IRB. After local IRB approvals
were received, these were sent back to the IRB at JHSPH as
amendments to the PERCH protocol. Only after these amend-
ments were received and approved at JHSPH—that is, after
both JHSPH and local approvals had been obtained—was
any enrollment conducted at the sites. This process has
helped to assure that all appropriate IRBs have had a chance
to review the protocol. In addition, regular reporting of
patient status to the JHSPH IRB occurs throughout the
course of the project.
The PERCH project has deﬁned a governance structure
that allows for collective ownership of the study across sites
while maintaining functional management systems. Table 2
and Figure 2 illustrates the roles and responsibilities of each
group involved in study governance. The executive com-
mittee, comprising the principal investigator for each site
plus 3 members of the PERCH core team, has responsibility
for the overall governance of the study and for resolution of
issues that cross sites. The PERCH expert group provides
strategic advice and brings key expertise to the study. The 4
working groups meet regularly to address and/or resolve key
issues with respect to the design of the study, and the op-
erational team helps to monitor regular progress in the
implementation of the protocol at each site and to identify
and resolve issues that emerge.
SUMMARY
We expect PERCH to provide important results to the sci-
entiﬁc, public health, and policy communities that will in-
ﬂuence treatment algorithms, diagnostic approaches, and
vaccine development from 2015 onward. PERCH is designed
to generate estimates of the distribution of severe and very
severe pneumonia etiologies in children, of the incidence
of severe and very severe pneumonia in different epidemio-
logic settings, and of the important environmental and be-
havioral risk factors for severe and very severe pneumonia.
In addition, we anticipate that PERCH will inﬂuence pneu-
monia etiology research methods by revealing whether there
is added value of induced sputum or lung biopsy specimens
for detection of speciﬁc etiologies, and by enhancing our
understanding of the sensitivity and speciﬁcity of new di-
agnostic tools. Finally, by building a repository of carefully
collected biologic specimens and linking them with rigorously
documented clinical and epidemiologic data, PERCH is ex-
pected to contribute to pathogen discovery in thefuture, too.
PERCH is a large etiology study, but it does not stand
alone nor does it ﬁll all the key research gaps in the ﬁeld.
Fortunately, after a period of relatively little research into
pediatric pneumonia etiology in developing countries, the
PERCH project now ﬁnds itself as just one of many ongoing
or planned pneumonia studies that are contributing to a new
evidence base on pneumonia etiology. PERCH is not an in-
tervention study of either pneumonia treatment or pneu-
monia prevention strategies. In each of the study sites, local
pneumonia case management is provided without stan-
dardization across the sites. PERCH is also not explicitly
designed to evaluate interventions for pneumonia such as
vaccines, improved cookstoves, or oxygen therapy. Immu-
nization status and known or potential risk factors for
pneumonia will be collected as part of the PERCH study,
but the study does not include patients with meningitis,
sepsis, or other syndromes potentially preventable by Hib
and/or pneumococcal conjugate vaccines. In short, PERCH
provides one key piece of the evidence base, but other studies
are clearly needed.
As an observational etiology study, PERCH aims to pro-
vide a strong set of evidence to improve child survival and
to do so in a way that is transparent and widely accessible.
The PERCH protocol, standard operating procedures,
and case report forms are all publicly available through the
Internet by visiting http://www.jhsph.edu/ivac/perch.html.
Through this series of papers, we aim to describe the issues
that we debated in the course of designing the study and
hope that by sharing these lessons with the pneumonia re-
search community, we will help other investigators con-
ducting pneumonia research elsewhere.
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